Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?

Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?

Modulation of the immune system has been demonstrated as a powerful approach to treating cancer. Immunotherapies are generally classified as active or passive according to their ability to trigger the immune system. During the last decades, information regarding the relevance of aberrant glycosylati...

Full description

Saved in:
Bibliographic Details
Published in:Immuno Vol. 3; no. 2; pp. 122 - 147
Main Authors: Segatori, Valeria Inés, Ferreira, Gretel Magalí, Rojo, Selene, Nogueira, Aylen Camila, Castillo, Jeremías Omar, Gulino, Cynthia Antonella, Gabri, Mariano Rolando
Format: Journal Article
Language:English
Published: Sapporo MDPI AG 01-06-2023
Subjects:
aberrant glycosylation
active immunotherapy
Antibodies
Antigens
Breast cancer
cancer
Genes
Genetic engineering
Genotype & phenotype
Immune system
Immunology
Immunotherapy
Melanoma
mimicry
Mutation
Peptides
Physiology
Prostate
Proteins
Stem cells
TACA
Viral infections
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Modulation of the immune system has been demonstrated as a powerful approach to treating cancer. Immunotherapies are generally classified as active or passive according to their ability to trigger the immune system. During the last decades, information regarding the relevance of aberrant glycosylation as a major player in tumour biology encouraged expectations for the development of new therapeutic strategies directed at glycans. Several tumour-associated carbohydrate antigens (TACAs) have been identified and validated as suitable immunotherapeutic targets, leading to promising therapeutic developments. It is known that TACAs are poorly immunogenic since they are unable to trigger a proper immune response. Given that they are not presented by major histocompatibility complex (MHC) molecules and that they induce immune tolerance, the development of active immunotherapeutic strategies against TACAs is a real challenge. However, antitumor strategies based on mimetics of TACAs have been developed and show promising results. Active immunotherapies based on TACAs mimicry can currently be grouped into strategies based on the use of mimetic peptides and anti-idiotype (Id) antibodies. In this review, we discussed the scientific basis on which these strategies are based and the available therapeutic options that have shown the best results in preclinical studies and in clinical practice.
ISSN:2673-5601
2673-5601
DOI:10.3390/immuno3020009